Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.

Nominal P values for quality of life, as measured by the proportion of patients achieving DLQI 0/1 or CDLQI 0/1, did not reach statistical significance for both upadacitinib doses across the studies, likely because the sample size was split between 2 assessments, as neither are validated for the entire adolescent age range studied and the very high bar set for the analysis of these end points.

also in 111,027 other papers